Anastrozole (ARIMIDEX) is not recommended for use in children or in premenopausal women as safety and efficacy have not been established in these groups of patients (see Pharmacology: Pharmacodynamics under Actions and Pharmacology: Pharmacokinetics under Actions).
Anastrozole (ARIMIDEX) has not been investigated in patients with severe hepatic or severe renal impairment. The potential risk/benefit to such patients should be carefully considered before administration of Anastrozole (ARIMIDEX).
As Anastrozole (ARIMIDEX) lowers circulating estrogen levels it may cause a reduction in bone mineral density with a possible consequent increased risk of fracture. This possible increased risk should be managed according to treatment guidelines for managing bone health in postmenopausal women.
Effects on ability to drive and use machines: Anastrozole (ARIMIDEX) is unlikely to impair the ability of patients to drive or operate machinery. However, asthenia and somnolence have been reported with the use of Anastrozole (ARIMIDEX) and caution should be observed when driving or operating machinery while such symptoms persists.